Literature DB >> 35662591

Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.

Geoffrey D E Cuvelier1, Michelle Schoettler2, Nataliya P Buxbaum3, Iago Pinal-Fernandez4, Marc Schmalzing5, Jörg H W Distler6, Olaf Penack7, Bianca D Santomasso8, Robert Zeiser9, Klemens Angstwurm10, Kelli P A MacDonald11, W Taylor Kimberly12, Naomi Taylor13, Ervina Bilic14, Bernhard Banas15, Maike Buettner-Herold16, Namita Sinha17, Hildegard T Greinix18, Joseph Pidala19, Kirk R Schultz20, Kirsten M Williams21, Yoshihiro Inamoto22, Corey Cutler23, Linda M Griffith24, Stephanie J Lee25, Stefanie Sarantopoulos26, Steven Z Pavletic27, Daniel Wolff28.   

Abstract

Alloreactive and autoimmune responses after allogeneic hematopoietic cell transplantation can occur in nonclassical chronic graft-versus-host disease (chronic GVHD) tissues and organ systems or manifest in atypical ways in classical organs commonly affected by chronic GVHD. The National Institutes of Health (NIH) consensus projects were developed to improve understanding and classification of the clinical features and diagnostic criteria for chronic GVHD. Although still speculative whether atypical manifestations are entirely due to chronic GVHD, these manifestations remain poorly captured by the current NIH consensus project criteria. Examples include chronic GVHD impacting the hematopoietic system as immune mediated cytopenias, endothelial dysfunction, or as atypical features in the musculoskeletal system, central and peripheral nervous system, kidneys, and serous membranes. These purported chronic GVHD features may contribute significantly to patient morbidity and mortality. Most of the atypical chronic GVHD features have received little study, particularly within multi-institutional and prospective studies, limiting our understanding of their frequency, pathogenesis, and relation to chronic GVHD. This NIH consensus project task force report provides an update on what is known and not known about the atypical manifestations of chronic GVHD while outlining a research framework for future studies to be undertaken within the next 3 to 7 years. We also provide provisional diagnostic criteria for each atypical manifestation, along with practical investigation strategies for clinicians managing patients with atypical chronic GVHD features.
Copyright © 2022 The American Society for Transplantation and Cellular Therapy. All rights reserved.

Entities:  

Keywords:  Atypical; Chronic graft-versus-host disease; National Institutes of Health Consensus Project Task Force

Mesh:

Year:  2022        PMID: 35662591      PMCID: PMC9557927          DOI: 10.1016/j.jtct.2022.05.038

Source DB:  PubMed          Journal:  Transplant Cell Ther        ISSN: 2666-6367


  207 in total

1.  Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.

Authors:  R A Levy; V S Vilela; M J Cataldo; R C Ramos; J L Duarte; B R Tura; E M Albuquerque; N R Jesús
Journal:  Lupus       Date:  2001       Impact factor: 2.911

2.  Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.

Authors:  Nicolaus Kröger; Maria Zagrivnaja; Sabine Schwartz; Anita Badbaran; Tatjana Zabelina; Michael Lioznov; Francis Ayuk; Axel Zander; Boris Fehse
Journal:  Exp Hematol       Date:  2006-05       Impact factor: 3.084

3.  Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation.

Authors:  Dipenkumar Modi; Hyejeong Jang; Seongho Kim; Abhinav Deol; Lois Ayash; Divaya Bhutani; Lawrence G Lum; Voravit Ratanatharathorn; Richard Manasa; Kendra Mellert; Joseph P Uberti
Journal:  Am J Hematol       Date:  2016-07-14       Impact factor: 10.047

Review 4.  Autoimmune hematologic complications of umbilical cord blood transplantation.

Authors:  Uroosa Ibrahim; Alla Keyzner
Journal:  Hematol Oncol Stem Cell Ther       Date:  2020-08-26

Review 5.  Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH).

Authors:  Marta González-Vicent; Jaime Sanz; José Luis Fuster; Joan Cid; Cristina Díaz de Heredia; Daniel Morillo; José María Fernández; Antonia Pascual; Isabel Badell; David Serrano; Laura Fox; Javier de la Serna; Ana Benito; José Miguel Couselo; Blanca Molina; Miguel Ángel Díaz; Miguel Ángel Sanz
Journal:  Transfus Med Rev       Date:  2018-03-03

6.  Angiitis of the central nervous system after allogeneic bone marrow transplantation?

Authors:  C S Padovan; K Bise; J Hahn; P Sostak; E Holler; H J Kolb; A Straube
Journal:  Stroke       Date:  1999-08       Impact factor: 7.914

7.  Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia.

Authors:  Ehud Even-Or; Adeeb Naser Eddin; Bella Shadur; Yael Dinur Schejter; Mohammad Najajreh; Orly Zelig; Irina Zaidman; Polina Stepensky
Journal:  Pediatr Blood Cancer       Date:  2019-09-22       Impact factor: 3.167

8.  Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification.

Authors:  Zhenhuan Zhao; Jiling Ren; Chao Dai; Carol C Kannapell; Hongyang Wang; Felicia Gaskin; Shu Man Fu
Journal:  Ann Rheum Dis       Date:  2018-09-25       Impact factor: 19.103

9.  Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events.

Authors:  Priyanka A Pophali; Jeffrey K Klotz; Sawa Ito; Natasha A Jain; Eleftheria Koklanaris; Robert Q Le; Christopher S Hourigan; Bipin N Savani; Kamna Chawla; Sujata Shanbhag; A John Barrett; Minoo Battiwalla
Journal:  Exp Hematol       Date:  2013-10-17       Impact factor: 3.084

10.  Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.

Authors:  Catharina Schuetz; Manfred Hoenig; Despina Moshous; Christof Weinstock; Martin Castelle; Matthieu Bendavid; Kristin Shimano; Vanessa Tolbert; Ansgar S Schulz; Christopher C Dvorak
Journal:  Blood Adv       Date:  2018-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.